In the drugs best showing so far, the ATTAIN-1 trial, people taking orforglipron lost on average 12.4% of their baseline weight, a notch below the roughly 14% weight loss seen in similar trials of Novo Nordisks injectable Wegovy and also below the typical results seen with Eli Lillys tirzepatide, a dual GLP-1/GIP medication
8, e56710
David Perlmutter 41:28 I think job one, though, is to figure out what the heck your uric acid level is
[1] Unlike the folic acid derivative leucovorin, folic acid is not clinically useful in offsetting the action of folate reductase inhibitors because it requires the enzyme dihydrofolate reductase for activation
Both are large, multicenter, randomized, placebo- or semaglutide-controlled
The unexpected paradoxical worsening of psoriatic lesions after treatment with liraglutide was hypothesized to be due to cytokine imbalance with the release of IFN- and leukocyte chemotaxis after liraglutide-induced inhibition of TNF-, IL17, and IL23